Coventry University Featured PhD Programmes
Heriot-Watt University Featured PhD Programmes
University of Liverpool Featured PhD Programmes
University of Glasgow Featured PhD Programmes
University of Bristol Featured PhD Programmes
United Kingdom
Bradford×
10 miles

Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Bradford

We have 27 Pharmacology / Toxicology PhD Projects, Programs & Scholarships in Bradford

  • Pharmacology / Toxicology×
  • United Kingdom×
  • Bradford×
  • clear all
Order by 
Showing 1 to 15 of 27
  Targeting protein acetylation to reduce microglia activation in neurodegenerative disorders
  Research Group: School of Biomedical Sciences
  Dr I Wood, Dr L H Jiang
Application Deadline: 31 May 2019

Funding Type

PhD Type

Recently, inhibitors of histone deacetylase enzymes (HDACs) have been identified as having potential therapeutic value for a range of neuronal disorders including Alzheimer’s disease, dementia and stroke [1, 2].
  Cytochromes P450 in Cancer: Opportunities for Development of Personalised Medicine
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Prof P Loadman
Applications accepted all year round

Funding Type

PhD Type

The improved understanding of cancer biology provides opportunities for the development of molecular targeted therapies.
  Development of stimuli-responsive metallosupramolecular architectures for sensing and/or delivery of medicine for the treatment of solid tumours
  Research Group: Chemistry and Biosciences
  Dr D Petty, Dr M Najafzadeh, Dr S Pike
Applications accepted all year round

Funding Type

PhD Type

Applications are invited for a new self-funded PhD opportunity in the School of Chemistry & Biosciences at the University of Bradford.
  Targeting addiction to a breast cancer metastasis survival pathway by inhibition of RAN GTPase
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Prof M El-Tanani, Dr S Betmouni
Applications accepted all year round

Funding Type

PhD Type

Metastatic cancer is a major global health burden. Each year, eleven million new cases of cancer are diagnosed worldwide, including 5 million cases in industrialized countries.
  Ran GTPase as a potential novel therapeutic target in EMT transdifferentiation and breast cancer stem cell (BCSC) survival during metastatic development
  Research Group: Institute of Cancer Therapeutics
  Prof R Morgan, Prof M El-Tanani, Dr M Isreb, Dr M Najafzadeh
Applications accepted all year round

Funding Type

PhD Type

Breast cancer is the leading cause of cancer death in women worldwide. Accumulating evidence suggests that local disease recurrence and metastatic lesions, the major causes of patient mortality, are due to a subset of aggressive cells termed cancer stem cells (CSCs).
  Re-purposing established drugs for the resolution of pulmonary arterial hypertension (PAH)
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim
Applications accepted all year round

Funding Type

PhD Type

Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Impact of RhoA deregulation on smooth muscle cell phenotypic dysfunction in Type 2 diabetes
  Research Group: Chemistry and Biosciences
  Dr K Riches-Suman
Applications accepted all year round

Funding Type

PhD Type

Type 2 diabetes (T2D) is an escalating healthcare burden. It inflicts significant physical and emotional distress on patients and their carers, and treatment of T2D and its complications accounts for ~10% of the entire NHS budget.
  Aldehyde dehydrogenase expression and function in cancer stem cells
  Research Group: Institute of Cancer Therapeutics
  Dr K Pors, Dr A Mardaryev, Prof A Locke
Applications accepted all year round

Funding Type

PhD Type

Aldehyde dehydrogenases (ALDHs) catalyse the oxidation and detoxification of reactive endogenous and exogenous aldehydes into carboxylic acids via NAD+ coupled reduction.
  Pharmaceutical cocrystallisation for improved medicines
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr V Vangala, Prof A Paradkar
Applications accepted all year round

Funding Type

PhD Type

Active pharmaceutical ingredients (APIs) are frequently delivered to the patients in the solid-state formulation. Yet, therapeutic effectiveness of a dosage form depends on the bioavailability, stability and also on the manufacturability of the dosage form.
  Identifying glucose-dependent mechanisms underlying risk factors for Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr S McLean
Applications accepted all year round

Funding Type

PhD Type

Several risk factors for Alzheimer’s disease including diabetes and midlife obesity are age-dependent and have an obvious metabolic component resulting in impaired glucose metabolism.
  Determining brain glycosylation in ageing and Alzheimer’s disease
  Research Group: Pharmacology and Experimental Therapeutics
  Dr R Williamson, Dr C Sutton
Applications accepted all year round

Funding Type

PhD Type

Increasing age is associated with lower levels of cognitive performance; concomitant with this is a decrease in brain glucose metabolism.
  Therapeutic resolution of pulmonary arterial hypertension (PAH) by natural products
  Research Group: Pharmacology and Experimental Therapeutics
  Dr T Nasim, Prof C Wright
Applications accepted all year round

Funding Type

PhD Type

Pulmonary arterial hypertension (PAH) is a devastating cardiovascular disorder which, if left untreated, leads to heart failure and death.
  Quantitative structure/skin-permeation relationships (QSPeRs); an investigation of the relevance of parameters determined with biomembrane-mimicking systems for the predictability of drug partitioning into skin
  Research Group: Medicines Development and Pharmaceutical Sciences
  Dr X Liu, Prof D J Tobin
Applications accepted all year round

Funding Type

PhD Type

The transdermal route has many advantages over other routes for the delivery of drugs with systemic activity. These include the ease of use (and withdrawal in the occurrence of side-effects), avoidance of first-pass metabolism, and improved patient compliance.
  Activity based proteomic probes for profiling CYP2W1 in cancer tissues
  Research Group: Institute of Cancer Therapeutics
  Dr C Sutton, Dr K Pors
Applications accepted all year round

Funding Type

PhD Type

Cytochromes P450 (CYPs) are a superfamily of mixed function oxidases of which CYP1-4 subfamily members are unique in their ability to oxidise drugs.
  Exploration of 5-fluorouracil resistance mechanisms in colorectal cancer using 5-FU-resistant xenograft models
  Research Group: Institute of Cancer Therapeutics
  Dr S Shnyder, Dr C Sutton
Applications accepted all year round

Funding Type

PhD Type

Despite therapeutic advances, colorectal cancer (CRC) still has a 45% mortality rate, and one of the major problems is the development of acquired resistance to treatment with anticancer drugs.
Show 10 15 30 per page


FindAPhD. Copyright 2005-2019
All rights reserved.